Personalized radiation therapy and biomarker-driven treatment strategies: a systematic review

[1]  R. Fisher,et al.  Prognostic Significance of Plasma Osteopontin in Patients with Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Treated on TROG 02.02 Phase III Trial , 2011, Clinical Cancer Research.

[2]  P. Kienle,et al.  KRAS and BRAF mutations and PTEN expression do not predict efficacy of cetuximab-based chemoradiotherapy in locally advanced rectal cancer. , 2011, International journal of radiation oncology, biology, physics.

[3]  David D. Smith,et al.  Identification of a Biomarker Profile Associated With Resistance to Neoadjuvant Chemoradiation Therapy in Rectal Cancer , 2011, Annals of surgery.

[4]  Hein Putter,et al.  Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. , 2011, The Lancet. Oncology.

[5]  R. Fisher,et al.  Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  M. Sydes,et al.  Expression of Bcl-2, p53, and MDM2 in localized prostate cancer with respect to the outcome of radical radiotherapy dose escalation. , 2010, International journal of radiation oncology, biology, physics.

[7]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[8]  J. Ragoussis,et al.  hsa‐miR‐210 is a marker of tumor hypoxia and a prognostic factor in head and neck cancer , 2010, Cancer.

[9]  T. Nielsen,et al.  Breast cancer subtypes and the risk of local and regional relapse. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  S. Paik,et al.  Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Oza,et al.  Phase 1 Study of Tirapazamine in Combination With Radiation and Weekly Cisplatin in Patients With Locally Advanced Cervical Cancer , 2010, International Journal of Gynecologic Cancer.

[12]  Howard Colman,et al.  MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. , 2010, Neuro-oncology.

[13]  G. Reifenberger,et al.  NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Reifenberger,et al.  Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  H. Hollema,et al.  Expression of Epidermal Growth Factor Receptor (EGFR) and Activated EGFR Predict Poor Response to (Chemo)radiation and Survival in Cervical Cancer , 2009, Clinical Cancer Research.

[16]  I. Nagtegaal,et al.  PIK3CA Mutations Predict Local Recurrences in Rectal Cancer Patients , 2009, Clinical Cancer Research.

[17]  A. Iafrate,et al.  MGMT METHYLATION IS A PROGNOSTIC BIOMARKER IN ELDERLY PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA , 2009, Neurology.

[18]  M. Seong,et al.  Low initial human papilloma viral load implicates worse prognosis in patients with uterine cervical cancer treated with radiotherapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Andrew J Vickers,et al.  Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Hammond,et al.  The Importance of Protein Kinase A in Prostate Cancer: Relationship to Patient Outcome in Radiation Therapy Oncology Group Trial 92-02 , 2009, Clinical Cancer Research.

[21]  Kyounghwa Bae,et al.  MDM2 and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy and androgen deprivation for prostate cancer: RTOG 92-02. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. Roach,et al.  Predictive models in external beam radiotherapy for clinically localized prostate cancer , 2009, Cancer.

[23]  M. J. van de Vijver,et al.  Local Recurrence after Breast-Conserving Therapy in Relation to Gene Expression Patterns in a Large Series of Patients , 2009, Clinical Cancer Research.

[24]  J. Weidhaas,et al.  Changes in Gene Expression Predicting Local Control in Cervical Cancer: Results from Radiation Therapy Oncology Group 0128 , 2009, Clinical Cancer Research.

[25]  E. Perez,et al.  Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  Jens Overgaard,et al.  Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  Caterina Giannini,et al.  Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  R. Jenkins,et al.  Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. , 2008, Cancer journal.

[29]  D. Grignon,et al.  Protein kinase A RI-alpha predicts for prostate cancer outcome: analysis of radiation therapy oncology group trial 86-10. , 2008, International journal of radiation oncology, biology, physics.

[30]  Lars Påhlman,et al.  Randomized phase III study comparing preoperative radiotherapy with chemoradiotherapy in nonresectable rectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  E. Domany,et al.  Stem cell-related "self-renewal" signature and high epidermal growth factor receptor expression associated with resistance to concomitant chemoradiotherapy in glioblastoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  D. Grignon,et al.  Ten-year follow-up of radiation therapy oncology group protocol 92-02: a phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Barbara L. Smith,et al.  Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  A. Brandes,et al.  MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  W. Westra,et al.  Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. , 2008, Journal of the National Cancer Institute.

[36]  D. Grignon,et al.  Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  A. Iafrate,et al.  Molecular Diagnostic Testing in Malignant Gliomas: A Practical Update on Predictive Markers , 2008, Journal of neuropathology and experimental neurology.

[38]  A. Ardizzoni,et al.  Biological predictive factors in rectal cancer treated with preoperative radiotherapy or radiochemotherapy , 2007, British Journal of Cancer.

[39]  D. Grignon,et al.  Prognostic value of abnormal p53 expression in locally advanced prostate cancer treated with androgen deprivation and radiotherapy: a study based on RTOG 9202. , 2007, International journal of radiation oncology, biology, physics.

[40]  E. Taioli,et al.  Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: Review and meta‐analysis , 2007, International journal of cancer.

[41]  D. Grignon,et al.  COX-2 expression predicts prostate-cancer outcome: analysis of data from the RTOG 92-02 trial. , 2007, The Lancet. Oncology.

[42]  H. Bartelink,et al.  Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  M. Kattan,et al.  Pretreatment nomogram predicting ten-year biochemical outcome of three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for prostate cancer. , 2007, Urology.

[44]  Christopher U. Jones,et al.  Microvessel Density ≥60 Does Not Predict for Outcome After Radiation Treatment for Locally Advanced Head and Neck Squamous Cell Carcinoma: Results of a Correlative Study From the Radiation Therapy Oncology Group (RTOG) 90-03 Trial , 2007, American journal of clinical oncology.

[45]  Laurence Collette,et al.  Impact of a Higher Radiation Dose on Local Control and Survival in Breast-Conserving Therapy of Early Breast Cancer: 10-Year Results of the Randomized Boost Versus No Boost EORTC 22881-10882 Trial , 2007 .

[46]  D. Grignon,et al.  Prognostic value of p16 in locally advanced prostate cancer: a study based on Radiation Therapy Oncology Group Protocol 9202. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  H. Sandler,et al.  Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02 , 2007, Clinical Cancer Research.

[48]  C. Sotiriou,et al.  Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patients , 2007, British Journal of Cancer.

[49]  M. Agostini,et al.  A haplotype of the methylenetetrahydrofolate reductase gene predicts poor tumor response in rectal cancer patients receiving preoperative chemoradiation , 2006, Pharmacogenetics and genomics.

[50]  C. Sempoux,et al.  Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[51]  I. Brandslund,et al.  Prediction of response to chemoradiation in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. , 2006, International journal of radiation oncology, biology, physics.

[52]  K. Song,et al.  Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. , 2006, International journal of radiation oncology, biology, physics.

[53]  Christine H Chung,et al.  Increased epidermal growth factor receptor gene copy number is associated with poor prognosis in head and neck squamous cell carcinomas. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[54]  Walter Curran,et al.  Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  O. Olopade,et al.  Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  Yoko Yamamoto,et al.  Prediction of sensitivity of rectal cancer cells in response to preoperative radiotherapy by DNA microarray analysis of gene expression profiles. , 2006, Cancer research.

[57]  Christopher U. Jones,et al.  Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. , 2006, The New England journal of medicine.

[58]  R. Collins,et al.  Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[59]  Min Zhang,et al.  Prognostic value of survivin in locally advanced prostate cancer: study based on RTOG 8610. , 2005, International journal of radiation oncology, biology, physics.

[60]  J. Overgaard,et al.  Plasma osteopontin, hypoxia, and response to the hypoxia sensitiser nimorazole in radiotherapy of head and neck cancer: results from the DAHANCA 5 randomised double-blind placebo-controlled trial. , 2005, The Lancet. Oncology.

[61]  D. Brizel,et al.  Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[62]  K. Trott,et al.  Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  W. Landuyt,et al.  The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy ± chemotherapy , 2005, BMC Cancer.

[64]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[65]  R. Simon,et al.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[66]  R. Mirimanoff,et al.  MGMT gene silencing and benefit from temozolomide in glioblastoma. , 2005, The New England journal of medicine.

[67]  Howard Y. Chang,et al.  Robustness, scalability, and integration of a wound-response gene expression signature in predicting breast cancer survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[68]  L. Cerezo,et al.  The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[69]  D. Grignon,et al.  Ki-67 Staining Index Predicts Distant Metastasis and Survival in Locally Advanced Prostate Cancer Treated With Radiotherapy , 2004, Clinical Cancer Research.

[70]  M. Hammond,et al.  Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  J. Lee,et al.  Synchronous Coexpression of Epidermal Growth Factor Receptor and Cyclooxygenase-2 in Carcinomas of the Uterine Cervix , 2004, Clinical Cancer Research.

[72]  Tak-Hong Cheung,et al.  Expression genomics of cervical cancer: molecular classification and prediction of radiotherapy response by DNA microarray. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  Kenji Tada,et al.  Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.

[74]  P. Okunieff,et al.  Loss of p16 expression is of prognostic significance in locally advanced prostate cancer: an analysis from the Radiation Therapy Oncology Group protocol 86-10. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  L. Mazzucchelli,et al.  Significant correlation of hypoxia-inducible factor-1alpha with treatment outcome in cervical cancer treated with radical radiotherapy. , 2003, International journal of radiation oncology, biology, physics.

[76]  R. Pötter,et al.  Overexpression of hypoxia-inducible factor 1alpha indicates diminished response to radiotherapy and unfavorable prognosis in patients receiving radical radiotherapy for cervical cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[77]  Johan Bussink,et al.  Tumor hypoxia at the micro-regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[78]  S. Clarke,et al.  p53, Deleted in Colorectal Cancer Gene, and Thymidylate Synthase as Predictors of Histopathologic Response and Survival in Low, Locally Advanced Rectal Cancer Treated With Preoperative Adjuvant Therapy , 2003, Diseases of the colon and rectum.

[79]  M. Marton,et al.  A Gene-Expression Signature as a Predictor of Survival in Breast Cancer , 2002 .

[80]  Ruth Katz,et al.  Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. , 2002, Cancer research.

[81]  R. Pötter,et al.  Impact of multiple HPV infection on response to treatment and survival in patients receiving radical radiotherapy for cervical cancer , 2002, International journal of cancer.

[82]  Y. Harima,et al.  Human papilloma virus (HPV) DNA associated with prognosis of cervical cancer after radiotherapy. , 2002, International journal of radiation oncology, biology, physics.

[83]  G Starkschall,et al.  Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  G S Bauman,et al.  Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. , 2000, International journal of radiation oncology, biology, physics.

[85]  J. Logue,et al.  Vascular endothelial growth factor (VEGF) expression is a prognostic factor for radiotherapy outcome in advanced carcinoma of the cervix , 2000, British Journal of Cancer.

[86]  A. Hanlon,et al.  Dose selection for prostate cancer patients based on dose comparison and dose response studies. , 2000, International journal of radiation oncology, biology, physics.

[87]  J. Poen,et al.  Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene. , 1999, Cancer research.

[88]  M. J. van de Vijver,et al.  Risk factors for local recurrence after breast-conserving therapy for invasive carcinomas: a case-control study of histological factors and alterations in oncogene expression. , 1998, International journal of radiation oncology, biology, physics.

[89]  M. Dewhirst,et al.  Tumor hypoxia adversely affects the prognosis of carcinoma of the head and neck. , 1997, International journal of radiation oncology, biology, physics.

[90]  D. Grignon,et al.  p53 status and prognosis of locally advanced prostatic adenocarcinoma: a study based on RTOG 8610. , 1997, Journal of the National Cancer Institute.

[91]  R. Bast,et al.  Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. , 1996, Journal of the National Cancer Institute.

[92]  G. Paludetti,et al.  Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. , 1996, British Journal of Cancer.

[93]  J. Grandis,et al.  Elevated levels of transforming growth factor alpha and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. , 1993, Cancer research.

[94]  R. Heald,et al.  RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER , 1986, The Lancet.

[95]  Cyrus Chargari,et al.  Controversies and challenges regarding the impact of radiation therapy on survival. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[96]  C. Grau,et al.  The importance of haemoglobin level and effect of transfusion in HNSCC patients treated with radiotherapy--results from the randomized DAHANCA 5 study. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[97]  Jordi Giralt,et al.  Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. , 2010, The Lancet. Oncology.

[98]  D. Alberts,et al.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. , 2010, The Cochrane database of systematic reviews.

[99]  S. Bettelli,et al.  Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  F. Ducray,et al.  IDH1 and IDH2 mutations in gliomas. , 2009, The New England journal of medicine.

[101]  Lei Dong,et al.  Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. , 2008, International journal of radiation oncology, biology, physics.

[102]  L. Solin,et al.  Impact of concurrent versus sequential tamoxifen with radiation therapy in early-stage breast cancer patients undergoing breast conservation treatment. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[103]  R. Livingston,et al.  Sequencing of tamoxifen and radiotherapy after breast-conserving surgery in early-stage breast cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  P. Etienne,et al.  Supplemental Table S2 , 2012 .

[105]  H. Ishikawa,et al.  The effects of p53 status and human papillomavirus infection on the clinical outcome of patients with Stage IIIB cervical carcinoma treated with radiation therapy alone , 2001, Cancer.

[106]  S. Lundgren,et al.  Changes in radiation sensitivity and steroid receptor content induced by hormonal agents and ionizing radiation in breast cancer cells in vitro. , 1996, Acta oncologica.

[107]  HighWire Press,et al.  Journal of clinical oncology : official journal of the American Society of Clinical Oncology. , 1983 .